Contract Development and Manufacturing Organization Market

Contract Development and Manufacturing Organization Market Latest Trends

The Contract Development and Manufacturing Organization Market is shifting from transaction-based outsourcing toward long-term strategic partnerships covering multiple stages of a product lifecycle. Pharmaceutical and biotechnology companies increasingly prefer CDMOs capable of managing development, clinical supply, scale-up, validation, commercial manufacturing, and packaging within connected technical networks. This approach reduces handoffs between service providers and can simplify technology transfer, quality oversight, documentation, and manufacturing scheduling.

Advanced biologics are reshaping investment priorities across the sector. Samsung Biologics brought Plant 5 to CGMP readiness in 2025, strengthening large-scale mammalian manufacturing capability and integrating digital systems into its operating model. The company also expanded antibody-drug conjugate and organoid-related services, showing how major CDMOs are moving beyond conventional manufacturing toward integrated development platforms.

Highly potent molecules and antibody-drug conjugates are another major focus. CDMOs are investing in containment, payload-linker synthesis, bioconjugation, aseptic filling, and specialist analytical capabilities. Lonza's expansion activity in Visp reflects this transition toward integrated ADC manufacturing, where a provider can support drug substance, payload, conjugation, formulation, and drug-product operations within a coordinated network.

Digitalization is also moving deeper into production environments. Electronic quality systems, predictive maintenance, process analytics, automated material handling, artificial intelligence, and digital twins are being adopted to improve manufacturing consistency and support complex technology transfers. These investments are increasingly paired with flexible single-use equipment and modular production systems, enabling CDMOs to handle changing batch sizes and broader client portfolios without relying exclusively on fixed large-scale infrastructure.

Contract Development and Manufacturing Organization Market Dynamics

The Contract Development and Manufacturing Organization Market is shaped by pharmaceutical outsourcing, increasingly complex drug pipelines, regulatory demands, manufacturing-capacity requirements, and pressure to move candidates efficiently from development into commercial production. Contract manufacturing represented 58% of the broader healthcare CDMO market in 2024, confirming that manufacturing remains the largest outsourced service category. Sponsors increasingly evaluate CDMOs on technical capability, regulatory performance, speed of technology transfer, geographic redundancy, quality systems, and ability to scale production without changing partners. Biologics, sterile drugs, high-potency APIs, and advanced therapies require specialized infrastructure that can be difficult to maintain internally. At the same time, outsourcing creates dependence on external partners, making quality governance, intellectual-property protection, production scheduling, and supply continuity important commercial considerations. Consolidation is therefore occurring alongside specialization, with large integrated providers expanding end-to-end networks while niche CDMOs focus on technically demanding manufacturing processes.

Drivers of Market Growth

Increasing pharmaceutical and biotechnology manufacturing outsourcing.

Pharmaceutical companies increasingly use external development and manufacturing partners to access capacity, specialized scientific expertise, regulatory infrastructure, and flexible production without constructing dedicated facilities for every product. The U.S. healthcare CDMO market shows this pattern clearly, with small-molecule services holding 41.09% of the market by type in 2024 while biologics and other complex modalities continue gaining strategic importance. Outsourcing supports organizations that need manufacturing capabilities across APIs, finished dosage products, sterile filling, analytical development, clinical supply, packaging, and commercial production. Large pharmaceutical groups also use CDMOs to diversify supply networks and manage peaks in internal capacity requirements. Biotechnology companies frequently depend even more heavily on external manufacturers because their internal organizations are often focused on discovery and clinical development rather than commercial-scale production. Integrated CDMO models enable these sponsors to maintain technical continuity as programs move from laboratory development through process scale-up and regulatory validation. As drug pipelines become more specialized, access to proven external manufacturing platforms remains a major industry driver.

Market Restraints

Stringent regulatory, quality, and compliance requirements.

CDMOs operate in an environment where deviations, contamination events, data-integrity failures, documentation deficiencies, and unsuccessful inspections can disrupt customer programs and manufacturing schedules. Piramal reported successfully clearing 36 regulatory inspections during its FY2025 period without major observations, illustrating the level of continuous compliance activity required from global providers. CDMOs serving multiple clients must maintain validated equipment, controlled material flows, qualified personnel, robust analytical methods, electronic data governance, environmental monitoring, and detailed quality agreements across diverse programs. Regulatory differences between jurisdictions create further operational complexity because manufacturing sites can supply products into several markets governed by separate authorities. Advanced modalities intensify these requirements by introducing containment, chain-of-custody, cold-chain, aseptic, viral-safety, potency-testing, or specialized release-testing obligations. Smaller providers can face difficulty funding the systems and technical teams needed to remain inspection-ready. Consequently, compliance capability acts both as a barrier to entry and as a constraint on rapid capacity expansion, particularly when highly specialized manufacturing platforms are involved.

Market Opportunities

Expansion of biologics, ADCs, and advanced-therapy outsourcing.

Complex biological products are creating opportunities for CDMOs capable of providing cell-line development, process development, upstream production, downstream purification, conjugation, sterile filling, analytical testing, and commercial supply. Small molecules accounted for 36.70% of the broad healthcare CDMO market in 2024, leaving a substantial portion of outsourcing activity connected to large molecules, medical technologies, and other specialized platforms. Pharmaceutical pipelines increasingly include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, cell therapies, gene therapies, RNA-based medicines, and biosimilars. These products require facilities, specialized personnel, and quality systems that are expensive to replicate across individual drug developers. CDMOs that combine biologics manufacturing with high-potency chemistry and sterile drug-product capabilities are particularly well positioned for ADC programs because they can reduce transfers between separate vendors. New capacity in mammalian production, bioconjugation, payload manufacturing, viral vectors, and advanced aseptic processing demonstrates where service providers see sustained demand. Integrated scientific and manufacturing platforms therefore represent a major opportunity for differentiation.

Market Challenges

Managing capacity, technology transfer, and supply continuity across complex portfolios.

Large CDMOs must coordinate numerous client programs while balancing development batches, validation campaigns, commercial production, cleaning schedules, maintenance, and regulatory commitments. Samsung Biologics' Plant 5 added 180,000 liters of mammalian production capability, demonstrating the scale of infrastructure required to serve growing biologics portfolios. Such expansions create operating complexity because new equipment must be qualified, processes transferred, personnel trained, quality systems integrated, and customer campaigns scheduled without compromising existing commitments. Sponsors may also require rapid changes in batch volume when clinical results alter demand expectations. Supply-chain disruptions involving single-source raw materials, specialty excipients, disposable assemblies, chromatography materials, packaging components, or cold-chain logistics can affect production even when manufacturing equipment is available. Multi-site networks improve redundancy but also require standardized procedures and reliable technology transfer between facilities. CDMOs therefore face the continuing challenge of combining flexibility with regulatory control while maintaining dependable delivery across products that differ significantly in chemistry, biological complexity, manufacturing scale, and lifecycle stage.

Contract Development and Manufacturing Organization SWOT Analysis

Strengths

• CDMOs provide specialized manufacturing infrastructure that pharmaceutical developers can access without building dedicated internal capacity for each molecule or dosage form.

• Integrated service models improve continuity between development, analytical testing, scale-up, validation, commercial manufacturing, and packaging.

• Established providers possess regulatory experience across multiple inspection authorities, creating a strong operational advantage in complex pharmaceutical programs.

• Large global networks enable production to be allocated across multiple sites, while leading biologics CDMOs collectively operate facilities capable of handling commercial-scale programs with 784,000-liter site capacity at the upper end of the industry.

Weaknesses

• Outsourced manufacturing can reduce a sponsor's direct control over production scheduling, operational priorities, and equipment allocation.

• Technology transfers between development laboratories and commercial plants create additional validation and documentation requirements.

• Smaller CDMOs may lack the breadth of analytical, regulatory, sterile, biologics, or commercial capabilities offered by integrated global competitors.

• Capacity utilization can create bottlenecks, particularly when one facility serves numerous customer programs requiring specialized equipment or controlled manufacturing suites.

Opportunities

• Expansion into antibody-drug conjugates, cell therapy, gene therapy, RNA medicines, high-potency APIs, and biologics creates higher-value technical service opportunities.

• Regional supply-chain diversification is encouraging customers to qualify additional manufacturing sites and suppliers.

• Digital manufacturing systems can improve data visibility, production scheduling, deviation management, and technology-transfer consistency.

• Asia-Pacific held 26% of the global CDMO market in a 2026 geographic estimate, providing a significant base for further expansion of development and manufacturing capabilities.

Threats

• Regulatory enforcement actions can interrupt production and damage long-term customer confidence.

• Intense competition can create pricing pressure in standardized manufacturing categories where technical differentiation is limited.

• Geopolitical restrictions, trade measures, and supply-chain localization policies can influence where pharmaceutical companies place outsourcing contracts.

• Rapid changes in therapeutic platforms can reduce utilization of older assets if facilities cannot be adapted for new manufacturing technologies.

Contract Development and Manufacturing Organization Segmentation Analysis

The Contract Development and Manufacturing Organization Market can be evaluated by service, molecule type, therapeutic area, and end-user requirements. These dimensions reflect the technical and commercial differences between early-stage development programs and established commercial products. Contract manufacturing remains the largest service grouping because sponsors frequently outsource capital-intensive production, while development services are increasingly bundled into integrated contracts. Small molecules continue to represent a large installed base, but biologics and advanced therapies require specialized manufacturing platforms that support higher technical complexity. Therapeutic-area demand is influenced by drug pipelines and modality selection, with oncology playing a particularly important role in high-potency compounds, monoclonal antibodies, and ADC programs. End-user requirements differ substantially between global pharmaceutical companies and emerging biotechnology companies. Manufacturing services accounted for 58% of the broader healthcare CDMO market in 2024, indicating the continuing importance of production capacity within the overall service mix.

By Service

Contract Manufacturing includes API manufacturing, finished-product manufacturing, and packaging, while Contract Development includes formulation development, process development and scale-up, analytical-method development and validation, stability testing, and CMC and regulatory-development support. Drug-substance manufacturing represented 58.3% of one 2024 CDMO service assessment, highlighting the substantial role played by technically intensive API and biological drug-substance production. API manufacturing requires process control, impurity management, scale-up expertise, containment, analytical characterization, and validated equipment. Finished-product manufacturing extends these requirements into tablets, capsules, injectables, biologics, sterile dosage forms, and specialized delivery systems. Packaging is closely linked with serialization, labeling, stability, and commercial distribution. Development services support sponsors before routine manufacturing begins by refining formulations, defining critical process parameters, validating analytical methods, and generating stability evidence. CDMOs capable of connecting these stages can reduce repeated transfers of technical information and maintain a consistent manufacturing strategy from development through commercial supply.

By Molecule Type

Small Molecules remain an important segment because pharmaceutical portfolios continue to contain large numbers of chemically synthesized products supported by established manufacturing technologies and regulatory pathways. Small molecules accounted for 64.8% of one global CDMO molecule-type assessment for 2024. These programs require services including route development, process chemistry, API production, high-potency handling, formulation, oral solid dosage manufacturing, and sterile processing. Biologics involve more complex production systems based on living cells and require cell-line development, upstream culture, downstream purification, viral safety, and specialized analytical testing. Cell and Gene Therapies create additional manufacturing requirements involving viral vectors, cell processing, cryogenic handling, chain-of-identity controls, and small-batch personalized production. Other molecule categories can include peptides, oligonucleotides, RNA medicines, and emerging hybrid modalities. The molecule mix directly influences facility design because chemical synthesis, microbial production, mammalian cell culture, viral-vector manufacturing, and patient-specific cell processing require fundamentally different production technologies.

By Therapeutic Area

Oncology, Infectious Diseases, Neurology, Cardiology, Immunology & Inflammation, Metabolic Disorders, and other therapeutic areas create distinct outsourcing needs depending on molecule complexity, dosage form, manufacturing scale, and clinical-development activity. Oncology is especially influential because it incorporates small molecules, monoclonal antibodies, bispecific antibodies, cell therapies, high-potency compounds, and antibody-drug conjugates. Biologics represented 45% of one broad CDMO product-type assessment in 2024, with oncology and autoimmune indications identified as important demand areas for complex biological manufacturing. Infectious-disease programs require flexible capabilities for vaccines, antivirals, biologics, and rapid manufacturing scale-up. Neurology and cardiology portfolios continue to support small-molecule and specialty-formulation outsourcing, while immunology has become a major field for monoclonal antibodies and other targeted biological medicines. Metabolic-disease development is also expanding into injectable peptides and biological products. Therapeutic diversification helps CDMOs balance their project pipelines while rewarding providers able to manufacture multiple molecule types under separate controlled production environments.

By End User

Big Pharma, Small and Mid-size Pharmaceutical Companies, Generic Pharmaceutical Companies, Biotechnology Companies, and other customers use CDMOs for different strategic reasons. Biopharmaceutical companies accounted for 65.2% of the cell and gene therapy CDMO market by end user in 2024, demonstrating the strong dependence of advanced-therapy developers on external specialist manufacturing. Large pharmaceutical companies often use CDMOs to supplement internal capacity, support specific technologies, diversify geographic supply, or outsource non-core manufacturing. Small and mid-size pharmaceutical companies may rely on external providers for larger portions of product development and commercial supply. Generic manufacturers frequently require efficient API, formulation, scale-up, validation, and high-volume manufacturing capabilities. Biotechnology companies commonly operate asset-light models and can depend on CDMOs for early development, clinical production, commercial launch, and subsequent scale-up. These differences are encouraging CDMOs to create flexible commercial structures ranging from discrete services to fully integrated development and manufacturing programs.

Regional Analysis

Regional performance in the Contract Development and Manufacturing Organization Market reflects differences in pharmaceutical R&D concentration, manufacturing costs, regulatory systems, technical labor, infrastructure, and government policies. North America holds the largest position, while Asia-Pacific has developed into the second-largest CDMO geography and continues attracting manufacturing investment. Europe retains strong capabilities in complex chemistry, biologics, sterile manufacturing, and high-value pharmaceutical production. Middle East & Africa remains a smaller but developing outsourcing region supported by local pharmaceutical-manufacturing initiatives and healthcare investment. A 2026 geographic estimate placed North America at 42% of the global CDMO market, confirming its continuing leadership while also showing that significant capacity is distributed across Asia-Pacific and Europe.

• North America: North America represents the largest Contract Development and Manufacturing Organization Market region, supported by the concentration of pharmaceutical companies, biotechnology clusters, clinical-development activity, specialist manufacturing sites, and FDA-regulated supply infrastructure. The region accounted for 42% of the global CDMO market in a 2026 geographic industry estimate. U.S. sponsors outsource APIs, biologics, sterile injectables, oral solid dosage forms, clinical supplies, packaging, analytical testing, cell therapies, gene therapies, and high-potency products. Domestic manufacturing has also become strategically important as drug companies evaluate supply-chain resilience and seek alternative production sources for critical medicines. Major providers are expanding U.S. capacity through site acquisitions and brownfield investment. Thermo Fisher's addition of the Ridgefield sterile fill-finish site strengthened its domestic drug-product manufacturing network, while Lonza's integration of the Vacaville biologics facility expanded large-scale mammalian capability. North American CDMOs benefit from proximity to large customers and advanced research organizations but face high labor, construction, compliance, and operating costs. The region therefore competes most effectively in regulated and technically complex services where manufacturing quality, speed, intellectual-property protection, and scientific expertise are major customer priorities.

• Europe: Europe remains a major center for Contract Development and Manufacturing Organization Market activity, supported by pharmaceutical manufacturing expertise across Switzerland, Germany, France, Sweden, Spain, Italy, Belgium, Ireland, and the United Kingdom. Europe represented 22% of the global CDMO market in a 2026 geographic estimate. Regional providers have developed strong positions in APIs, drug-product manufacturing, biologics, microbial fermentation, sterile fill-finish, ophthalmic products, high-potency chemistry, and antibody-drug conjugates. Switzerland is especially important for biologics and complex chemistry, with major capacity operated by companies such as Lonza and Siegfried. Germany combines formulation-development capabilities with specialist dosage-form manufacturing, while France and Sweden support established contract-production networks. European CDMOs must operate under rigorous quality and environmental requirements, which can increase operating complexity but also strengthen their credibility for regulated global supply. Investment is increasingly directed toward highly differentiated manufacturing rather than commodity production. Recent expansions in ADC payload-linker manufacturing, ophthalmic drug production, microbial biologics, and aseptic filling illustrate the region's focus on technical specialization. Europe also benefits from experienced scientific and engineering workforces capable of supporting complex process development and technology-transfer programs.

• Asia-Pacific: Asia-Pacific has evolved from a cost-focused outsourcing destination into a major center for advanced pharmaceutical development and manufacturing. The region accounted for 26% of the global CDMO market in a 2026 geographic estimate, making it the second-largest geography. China, India, South Korea, Japan, and Singapore contain extensive manufacturing ecosystems covering APIs, formulations, biologics, biosimilars, sterile products, and advanced therapies. South Korea has become particularly important in large-scale biologics manufacturing, supported by major investments in mammalian-cell-culture capacity. India retains significant strengths in small-molecule chemistry, APIs, generic-drug manufacturing, process development, and increasingly differentiated CDMO services. China combines extensive chemistry infrastructure with biologics and research capabilities, while Japan supports high-quality specialist manufacturing and pharmaceutical innovation. Regional competition increasingly depends on regulatory track records, advanced technology, and ability to support global filings rather than labor-cost advantages alone. Asian CDMOs are also investing in cell and gene therapies, antibody-drug conjugates, biologics, and integrated research-to-manufacturing platforms. This changing capability mix is strengthening Asia-Pacific's role in global pharmaceutical supply chains.

• Middle East & Africa: Middle East & Africa remains a smaller Contract Development and Manufacturing Organization Market region but is developing as governments and pharmaceutical companies invest in local production, medicine security, biotechnology, and healthcare infrastructure. The region represented 3% of the global CDMO market in a 2026 geographic estimate. Gulf countries are supporting pharmaceutical localization programs intended to reduce import dependence and establish domestic manufacturing for essential and specialty medicines. Contract manufacturers can benefit from these policies by partnering with international pharmaceutical companies that need local production or regional distribution platforms. South Africa maintains one of the continent's stronger pharmaceutical manufacturing bases, while selected North African countries support generic-drug and formulation production. The region still faces constraints involving specialist workforce availability, advanced biologics infrastructure, raw-material dependence, and uneven regulatory environments. However, these limitations also create opportunities for technology transfer, joint ventures, training, and facility investment. CDMO development is expected to concentrate first in established pharmaceutical hubs and industrial zones where regulatory frameworks, logistics, utilities, and healthcare demand can support sustained manufacturing activity.

Competitive Landscape

The Contract Development and Manufacturing Organization Market is fragmented across global integrated providers, regional manufacturers, biologics specialists, API producers, sterile-product manufacturers, and advanced-therapy CDMOs. Competition is increasingly based on technical capabilities, quality records, manufacturing scale, geographic reach, development expertise, capacity availability, and ability to support products from early development through commercial supply. The leading biologics CDMO competitive group remained dispersed in 2024, with the top ten participants collectively representing 29% of that segment. This fragmentation allows specialist firms to compete effectively in narrow areas such as highly potent APIs, ophthalmic products, microbial biologics, viral vectors, antibody-drug conjugates, and sterile fill-finish.

Large providers are expanding through facility investments, acquisitions, and integrated-service platforms. Thermo Fisher combines drug development, clinical research, API, biologics, sterile manufacturing, packaging, and clinical-supply capabilities. Lonza operates extensive biologics, small-molecule, cell and gene, bioconjugation, and drug-product capabilities. Samsung Biologics focuses heavily on large-scale biologics while expanding into ADCs, development services, and early-stage screening. Other competitors such as Recipharm, Siegfried, CordenPharma, Piramal Pharma Solutions, Cambrex, Vetter, Delpharm, Jubilant Pharmova, Eurofins Scientific, and Almac compete through differentiated manufacturing technologies or regional specialization. Capacity access and execution reliability remain decisive because clients increasingly seek long-duration relationships covering technically complex products.

List of Top Contract Development and Manufacturing Organization Companies

• Thermo Fisher Scientific Inc. (U.S.)

• Lonza Group AG (Switzerland)

• Recipharm AB (Sweden)

• Samsung Biologics Co., Ltd. (South Korea)

• WuXi AppTec Co., Ltd. (China)

• Catalent Inc. (U.S.)

• Piramal Pharma Solutions (India)

• Siegfried Holding AG (Switzerland)

• CordenPharma International (Switzerland)

• Cambrex Corporation (U.S.)

• Vetter Pharma International GmbH (Germany)

• Delpharm (France)

• Jubilant Pharmova Limited (India)

• Eurofins Scientific (Luxembourg)

• Almac Group (U.K.)

Leading Companies by Market Share

• Lonza Group AG: Within the biologics CDMO competitive set, Lonza held a 4% market share in 2024 and maintained a leading position through extensive mammalian, microbial, drug-product, bioconjugation, and advanced-manufacturing capabilities.

• Samsung Biologics Co., Ltd.: Samsung Biologics also held a 4% share of the biologics CDMO competitive set in 2024, supported by large-scale mammalian manufacturing and continued capacity expansion.

Investment Trends & Opportunities

Investment in the Contract Development and Manufacturing Organization Market is increasingly concentrated in complex manufacturing platforms rather than standardized capacity. Major spending areas include biologics, antibody-drug conjugates, high-potency APIs, aseptic drug products, prefilled syringes, advanced therapies, specialty oral dosage forms, and digital manufacturing systems. Piramal Pharma Solutions announced an expansion program covering two U.S. facilities in 2025, illustrating how providers are directing capital toward integrated ADC and sterile-manufacturing capabilities.

Biologics capacity remains a major investment theme because commercial monoclonal antibodies and other large molecules require specialized upstream and downstream infrastructure. New facilities increasingly incorporate flexible bioreactor configurations, automation, digital batch systems, advanced purification, and multi-product production strategies. Investments are also extending downstream into fill-finish so CDMOs can retain client programs beyond drug-substance manufacturing.

Another opportunity is supply-chain localization. Pharmaceutical companies are evaluating manufacturing footprints in response to geopolitical risk, transportation disruption, and national medicine-security policies. This creates opportunities for CDMOs with manufacturing networks distributed across North America, Europe, and Asia-Pacific.

Specialist technologies can also generate opportunities for smaller providers. High-potency chemistry, controlled substances, ophthalmic products, peptides, oligonucleotides, microbial fermentation, lyophilization, and cell processing require technical expertise that cannot easily be replaced by standard pharmaceutical capacity. Investors are therefore evaluating not only physical scale but also scarcity value: facilities and technical teams capable of executing manufacturing processes that few competitors can perform reliably.

Product Innovation & Development

Product innovation in the Contract Development and Manufacturing Organization Market increasingly involves platform technologies that shorten development timelines, simplify scale-up, and improve manufacturability. Samsung Biologics has expanded development capabilities through technology platforms designed to improve cell-line performance, productivity, and product quality, while integrating these services with large-scale biologics manufacturing. Plant 5 reached CGMP readiness in 2025, supporting the company's strategy of combining standardized facility design with digital manufacturing systems.

Single-use bioprocessing is another important innovation area. Disposable bioreactors, fluid paths, filters, and transfer assemblies reduce cleaning requirements and can make facilities more flexible when switching between client products. Continuous processing and intensified upstream production are also being evaluated to increase output without proportionally expanding facility footprints.

Innovation is particularly strong in antibody-drug conjugates. These products require integration of biologics manufacturing, highly potent payload synthesis, linker chemistry, conjugation, purification, analytical testing, and sterile drug-product manufacturing. CDMOs are developing connected service models that bring these activities under coordinated quality and project-management systems.

Digital technologies are also becoming manufacturing tools rather than administrative systems. Artificial intelligence, digital twins, automated environmental monitoring, predictive maintenance, and real-time process analytics can support faster troubleshooting and stronger process control. Product development services are consequently becoming more data-intensive, allowing CDMOs to provide customers with deeper process understanding before commercial scale-up begins.

Recent Developments (2023–2026)

In June 2026, Lonza announced an expansion of its Visp payload-linker manufacturing operations to strengthen commercial-scale support for highly potent compounds used in antibody-drug conjugates.

In October 2025, Recipharm inaugurated new parenteral-development and sterility laboratories in Bengaluru to expand sterile pharmaceutical development, analytical testing, and transition support into GMP manufacturing.

In September 2025, Thermo Fisher Scientific completed the acquisition of Sanofi's Ridgefield sterile fill-finish facility to expand U.S. drug-product manufacturing capacity within its pharmaceutical-services network.

In June 2025, Piramal Pharma Solutions began expansion work at U.S. manufacturing facilities supporting sterile injectables and integrated antibody-drug conjugate programs.

In May 2025, Siegfried announced additional ophthalmic manufacturing expansion at its El Masnou site in Spain to strengthen sterile eye-drop production for European customers.

In September 2024, Lonza completed the expansion of its microbial manufacturing facility in Visp, adding GMP-qualified production capability for microbially derived biologics.

Scope of the Contract Development and Manufacturing Organization Market Report

The Contract Development and Manufacturing Organization Market report covers the outsourced pharmaceutical development and manufacturing ecosystem across service categories, molecule types, therapeutic applications, end users, competitive strategies, investment activity, technological development, and regional manufacturing trends. The analysis evaluates Contract Manufacturing activities including API manufacturing, finished-product production, and packaging, together with Contract Development activities such as formulation development, process development and scale-up, analytical-method development and validation, stability testing, and CMC support.

The molecule analysis covers Small Molecules, Biologics, Cell & Gene Therapies, and other advanced pharmaceutical modalities. Therapeutic coverage includes Oncology, Infectious Diseases, Neurology, Cardiology, Immunology & Inflammation, Metabolic Disorders, and other indications. End-user analysis evaluates Big Pharma, Small and Mid-size Pharmaceutical Companies, Generic Pharmaceutical Companies, Biotechnology Companies, and other customer groups.

Regional coverage examines North America, Europe, Asia-Pacific, and Middle East & Africa, with attention to manufacturing infrastructure, regulatory environments, capacity investment, technical specialization, outsourcing patterns, and supply-chain considerations. North America accounted for 42% of the global CDMO market in a 2026 geographic estimate and serves as the benchmark region for large-scale pharmaceutical outsourcing activity.

The report also evaluates competitive positioning among global and specialist CDMOs, focusing on biologics expansion, sterile manufacturing, ADC capabilities, API technologies, facility acquisitions, digital manufacturing, quality systems, and integrated development-to-commercial strategies. Investment and innovation coverage highlights how CDMOs are adapting their networks to serve increasingly complex pharmaceutical pipelines.